Brief: Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers

Chemomab Therapeutics

27/03/2025 12:32

March 27 (Reuters) - Chemomab Therapeutics Ltd CMMB.O:

CHEMOMAB REPORTS POSITIVE RESULTS IN NEBOKITUG PHASE 2 PSC OPEN LABEL EXTENSION TRIAL SHOWING CONTINUED BROAD AND SUBSTANTIAL IMPROVEMENTS IN KEY LIVER BIOMARKERS

CHEMOMAB THERAPEUTICS LTD - TREATMENT FOR UP TO 48 WEEKS WAS WELL-TOLERATED

CHEMOMAB THERAPEUTICS- REINFORCES AND EXPANDS POSITIVE RESULTS FROM 15-WEEK DOUBLE-BLIND PHASE 2 SPRING TRIAL

Source text: ID:nGNXbPbd3d

Further company coverage: CMMB.O

 ((Reuters.Briefs@thomsonreuters.com;))